TY - JOUR
T1 - Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with
rheumatoid arthritis
AU - Tolusso, Barbara
AU - Frezza, Domenico
AU - Mattioli, Claudia
AU - Fedele, Anna Laura
AU - Bosello, Silvia Laura
AU - Faustini, Francesca
AU - Peluso, Giusy
AU - Giambra, Vincenzo
AU - Pietrapertosa, Donatello
AU - Morelli, Alessia
AU - Gremese, Elisa
AU - De Santis, Maria
AU - Ferraccioli, Gianfranco
PY - 2009
Y1 - 2009
N2 - Objective: To investigate the role of the HS1.2 enhancer polymorphisms as a new candidate marker for rheumatoid arthritis (RA) and to define the possible association with autoantibody positivity and clinical outcome. Methods: Genomic DNA was obtained from two cohorts of patients with RA (100 with early RA (ERA) and 114 with longstanding RA (LSRA)) and from 248 gender-matched controls from the same geographical area. Clinical and immunological characteristics were recorded for all the patients. Results: The percentage of the 2/2 genotype was higher In patients with ERA (27.0%), and In patients with LSRA (34.2%), than In controls (14.9%) (ERA: OR = 2.11 (95% Cl 1.20 to 3.70) vs controls; LSRA: OR = 2.96 (95% Cl 1.76 to 5.00) vs controls). A lower representation of allele *3 was present In patients with ERA (2.0%) than In controls (6.0%; OR = 0.32 (95% Cl 0.11 to 0.91)). No significant associations were found between polymorphisms and autoantibodies positivity. Conclusion: The HS1.2A allele *2 associates with early and longstanding RA.
AB - Objective: To investigate the role of the HS1.2 enhancer polymorphisms as a new candidate marker for rheumatoid arthritis (RA) and to define the possible association with autoantibody positivity and clinical outcome. Methods: Genomic DNA was obtained from two cohorts of patients with RA (100 with early RA (ERA) and 114 with longstanding RA (LSRA)) and from 248 gender-matched controls from the same geographical area. Clinical and immunological characteristics were recorded for all the patients. Results: The percentage of the 2/2 genotype was higher In patients with ERA (27.0%), and In patients with LSRA (34.2%), than In controls (14.9%) (ERA: OR = 2.11 (95% Cl 1.20 to 3.70) vs controls; LSRA: OR = 2.96 (95% Cl 1.76 to 5.00) vs controls). A lower representation of allele *3 was present In patients with ERA (2.0%) than In controls (6.0%; OR = 0.32 (95% Cl 0.11 to 0.91)). No significant associations were found between polymorphisms and autoantibodies positivity. Conclusion: The HS1.2A allele *2 associates with early and longstanding RA.
KW - HS12 enhancer
KW - rheumatoid arthritis
KW - HS12 enhancer
KW - rheumatoid arthritis
UR - https://publicatt.unicatt.it/handle/10807/31722
UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=61449244651&origin=inward
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=61449244651&origin=inward
U2 - 10.1136/ard.2008.095414
DO - 10.1136/ard.2008.095414
M3 - Article
SN - 0003-4967
VL - 68
SP - 416
EP - 419
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 3
ER -